← All verdicts
Verdict

Data Unavailable

Every analyzed stock in Data Unavailable — 2,921 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
"Data Unavailable" by: Model value (price vs DCF) Owner-earnings return (equity bond)

This lens: price against our probability-weighted DCF value (P/IV). Its own forward record began accruing on 2026-09-10 (daily snapshots); until a year of it exists, the panel below tests the nearest cousin we can measure point-in-time — cheap on book value — and says so.

Market state today: Calm — the S&P 500 closed 2.0% below its 1-year high (as of 2026-09-17). Our rule, the same one used to split every backtest on this site: sell-off = 10% or more below the 1-year high, borderline from 5%, calm otherwise. A further 8.2% fall from here would put us in a sell-off. Since 2006 the market has been in a sell-off 16.6% of the time, across 13 episodes (red bands).
2007200920112013201520172019202120232025
S&P 500 (SPY, adjusted) distance from its trailing 1-year high, weekly. Amber band: borderline (−5% to −10%). Red band: sell-off (below −10%). The dot is today. History to 2026-08-19 from the research database; today from the live feed.
Backtest · point in time · 8,702 entries in the study

Does this screen work? The record for exactly these filters

Screen tested: Proxy: price-to-book ≤ 1.2 (undervalued band has no point-in-time history yet) · bought the day of the annual report, held 12 months
Probable Buy every company that met this screen on the day it filed its annual report, hold 12 months: on average it beat the S&P 500 by +12.6 pts (1,427 entries, 311 companies, very unlikely to be luck). 50% of entries beat the S&P; 25% beat it by 30 points or more; 30% trailed it by 20 points or more. Owning everything instead averaged +1.7 pts, so the screen's edge is +10.9 pts.
+12.6 ptsvs S&P, average
50%beat the S&P
25%up 30+ pts vs S&P
30%down 20+ pts vs S&P
+14.0 ptsvs small caps, 12 mo
−15.1 pts 2019worst year to buy ?
6.1luck check ?
Does the holding period matter?3 mo: +2.3 pts 49% beat6 mo: +4.6 pts 49% beat12 mo: +12.6 pts 50% beat24 mo: +21.8 pts 46% beat3 yr, per yr: +1.3 pts 40% beat
Market state at entryCompany-yearsvs S&P 12 movs small caps
Calm ◀ today1,245+7.9 pts t 4.6+10.1 pts
Sell-off (S&P ≥10% off high)182+44.5 pts t 4.0+40.7 pts
Sector (SEC group)nvs S&P 12 mo3 yrs / yr
Industrials & manufacturing466+13.0 pts t 4.0−2.2 pts
Energy126+7.4 pts t 1.2−7.8 pts
Other115+8.4 pts t 1.8+3.8 pts
Tech hardware & semis113+10.9 pts t 1.6+2.3 pts
Services96+11.9 pts t 2.7+12.2 pts
Retail & consumer87+17.2 pts t 2.1+10.2 pts
Finance & real estate72−1.7 pts t -0.5−2.4 pts
Utilities65+5.6 pts t 0.6−1.2 pts
Construction53+13.2 pts t 1.7−2.4 pts
Biotech & pharma44+47.1 pts t 1.6+10.0 pts
Telecom & media43+14.0 pts t 0.7−6.3 pts
Software & IT services35+39.9 pts t 1.8+1.2 pts

Holds up out of sample? Before 2018: +10.7 pts (n 629, t 6.0). From 2018: +14.0 pts (n 798, t 4.1). Same sign in both halves.

Year2010201120122013201420152016201720182019202020212022202320242025
vs S&P+13 pts+5 pts+14 pts+18 pts−4 pts−4 pts+22 pts+12 pts−3 pts−15 pts+87 pts+8 pts+17 pts−9 pts−7 pts+15 pts
n254310610178841118178991297276108121115

Read the research behind this screen: Price-to-book still sorts, across all sizes → · Test your own combination in the Screen Lab →

Our model values are recomputed daily but were never stored historically, so this band cannot be backtested honestly yet. Daily snapshots began 2026-09-10; a true record accrues from there. Until then the nearest tested cousin is shown — cheap on book value — and labelled as a proxy. Point-in-time: each entry is one company bought at the first close after its 10-K filing date, using only filings available that day, held 12 months; result = total return minus SPY over the same months (vs IWM for 12 months; 3-yr annualised). Survivorship-tilted universe; no costs; read spreads, not levels. Educational, hypothetical, before costs.

Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
IIF
MORGAN STANLEY INDIA INVESTMENT FUND, INC.
Valuation N/A
Unknown
Price$22.42
Model IV—
P/IV—
Limited data — see page
IIM
Invesco Value Municipal Income Trust
Valuation N/A
Unknown
Price$12.11
Model IV—
P/IV—
Limited data — see page
IKT
Inhibikase Therapeutics, Inc.
Valuation N/A
Healthcare Risk 40 · Elevated
Price$2.34
Model IV—
P/IV—
Market implies +107.3%/yr vs model +2.0% · above model
ILAG
Intelligent Living Application Group Inc.
Valuation N/A
Consumer Cyclical Risk 33 · Moderate
Price$2.96
Model IV—
P/IV—
Market implies +11.0%/yr vs model +2.0% · above model
ILLR
Triller Group Inc.
Valuation N/A
Financial Services Risk 46 · Elevated
Price$0.73
Model IV—
P/IV—
Market implies +56.6%/yr vs model +17.2% · above model
ILLU
Illumination Acquisition Corp. I
Valuation N/A
Financial Services Risk 36 · Moderate
Price$9.98
Model IV—
P/IV—
Limited data — see page
ILMN
ILLUMINA, INC.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$206.45
Model IV—
P/IV—
Market implies +17.7%/yr vs model +3.0% · above model
ILPT
Industrial Logistics Properties Trust
Valuation N/A
Financial Services Risk 33 · Moderate
Price$7.73
Model IV—
P/IV—
Limited data — see page
IMA
ImageneBio, Inc.
Valuation N/A
Healthcare Risk 35 · Moderate
Price$5.00
Model IV—
P/IV—
Market implies +53.3%/yr vs model +2.0% · above model
IMCC
IM Cannabis Corp.
Valuation N/A
Healthcare Risk 49 · Elevated
Price$1.75
Model IV—
P/IV—
Limited data — see page
IMDX
Insight Molecular Diagnostics Inc.
Valuation N/A
Healthcare Risk 35 · Moderate
Price$4.20
Model IV—
P/IV—
Market implies +51.7%/yr vs model +16.5% · above model
IMKTA
INGLES MARKETS INC
Valuation N/A
Consumer Defensive
Price$83.12
Model IV—
P/IV—
Limited data — see page
IMMP
IMMUTEP Ltd
Valuation N/A
Healthcare Risk 52 · Elevated
Price$0.33
Model IV—
P/IV—
Limited data — see page
IMMR
IMMERSION CORP
Valuation N/A
Technology Risk 55 · Elevated
Price$7.40
Model IV—
P/IV—
Market implies -50.0%/yr vs model +50.0% · below model
IMMX
Immix Biopharma, Inc.
Valuation N/A
Healthcare Risk 27 · Moderate
Price$12.14
Model IV—
P/IV—
Limited data — see page
IMNM
Immunome Inc.
Valuation N/A
Healthcare Risk 35 · Moderate
Price$24.67
Model IV—
P/IV—
Market implies +103.6%/yr vs model +15.0% · above model
IMNN
Imunon, Inc.
Valuation N/A
Healthcare Risk 43 · Elevated
Price$1.47
Model IV—
P/IV—
Market implies +11.3%/yr vs model +15.0% · below model
IMO
IMPERIAL OIL LTD
Valuation N/A
Energy Risk 52 · Elevated
Price$129.99
Model IV—
P/IV—
Limited data — see page
IMOS
CHIPMOS TECHNOLOGIES INC
Valuation N/A
Technology Risk 27 · Moderate
Price$55.33
Model IV—
P/IV—
Limited data — see page
IMRN
Immuron Ltd
Valuation N/A
Healthcare Risk 40 · Elevated
Price$1.45
Model IV—
P/IV—
Limited data — see page
IMRX
Immuneering Corp
Valuation N/A
Healthcare Risk 29 · Moderate
Price$4.27
Model IV—
P/IV—
Market implies +93.3%/yr vs model +15.0% · above model
IMSR
Terrestrial Energy Inc. /DE/
Valuation N/A
Industrials Risk 42 · Elevated
Price$4.75
Model IV—
P/IV—
Market implies +138.2%/yr vs model +15.0% · above model
IMTE
Integrated Media Technology Ltd
Valuation N/A
Technology Risk 46 · Elevated
Price$0.46
Model IV—
P/IV—
Limited data — see page
IMTX
Immatics N.V.
Valuation N/A
Healthcare Risk 32 · Moderate
Price$8.62
Model IV—
P/IV—
Limited data — see page
IMUX
IMMUNIC, INC.
Valuation N/A
Healthcare Risk 36 · Moderate
Price$11.42
Model IV—
P/IV—
Limited data — see page
IMVT
Immunovant, Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$37.36
Model IV—
P/IV—
Limited data — see page
INAB
IN8BIO, INC.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$1.07
Model IV—
P/IV—
Limited data — see page
INAC
Indigo Acquisition Corp.
Valuation N/A
Financial Services Risk 34 · Moderate
Price$10.34
Model IV—
P/IV—
Limited data — see page
INACR
Indigo Acquisition Corp.
Valuation N/A
Financial Services Risk 43 · Elevated
Price$0.09
Model IV—
P/IV—
Limited data — see page
INBK
First Internet Bancorp
Valuation N/A
Financial Services Risk 55 · Elevated
Price$28.00
Model IV—
P/IV—
Market implies +42.8%/yr vs model +15.0% · above model
INBX
Inhibrx Biosciences, Inc.
Valuation N/A
Healthcare Risk 68 · High
Price$105.61
Model IV—
P/IV—
Market implies +150.0%/yr vs model +2.0% · above model
INCR
Intercure Ltd.
Valuation N/A
Healthcare Risk 44 · Elevated
Price$5.16
Model IV—
P/IV—
Limited data — see page
INDO
Indonesia Energy Corp Ltd
Valuation N/A
Energy Risk 26 · Moderate
Price$3.15
Model IV—
P/IV—
Market implies +39.1%/yr vs model +0.0% · above model
INDP
Indaptus Therapeutics, Inc.
Valuation N/A
Healthcare Risk 44 · Elevated
Price$3.14
Model IV—
P/IV—
Limited data — see page
INDV
Indivior Pharmaceuticals, Inc.
Valuation N/A
Healthcare Risk 35 · Moderate
Price$34.49
Model IV—
P/IV—
Market implies -5.4%/yr vs model +15.0% · below model
INFQ
Infleqtion, Inc.
Valuation N/A
Technology Risk 39 · Moderate
Price$13.12
Model IV—
P/IV—
Limited data — see page
INFY
Infosys Ltd
Valuation N/A
Technology Risk 46 · Elevated
Price$11.07
Model IV—
P/IV—
Limited data — see page
ING
ING GROEP NV
Valuation N/A
Financial Services Risk 43 · Elevated
Price$36.96
Model IV—
P/IV—
Limited data — see page
INHD
INNO HOLDINGS INC.
Valuation N/A
Basic Materials Risk 34 · Moderate
Price$3.96
Model IV—
P/IV—
Market implies +42.4%/yr vs model +0.0% · above model
INKT
MiNK Therapeutics, Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$12.00
Model IV—
P/IV—
Limited data — see page
INMB
Inmune Bio, Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$2.22
Model IV—
P/IV—
Market implies +123.8%/yr vs model +2.0% · above model
INO
INOVIO PHARMACEUTICALS, INC.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$1.25
Model IV—
P/IV—
Market implies +101.8%/yr vs model +2.0% · above model
INTC
INTEL CORP
Valuation N/A
Technology Risk 27 · Moderate
Price$97.19
Model IV—
P/IV—
Market implies +41.7%/yr vs model +0.0% · above model
INTR
Inter & Co, Inc.
Valuation N/A
Financial Services Risk 40 · Elevated
Price$5.71
Model IV—
P/IV—
Limited data — see page
INTS
INTENSITY THERAPEUTICS, INC.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$3.98
Model IV—
P/IV—
Limited data — see page
INTZ
INTRUSION INC
Valuation N/A
Technology Risk 37 · Moderate
Price$0.89
Model IV—
P/IV—
Market implies +41.8%/yr vs model +2.0% · above model
INV
Innventure, Inc.
Valuation N/A
Financial Services Risk 37 · Moderate
Price$0.94
Model IV—
P/IV—
Market implies +49.2%/yr vs model +50.0% · in line
INVZ
Innoviz Technologies Ltd.
Valuation N/A
Consumer Cyclical Risk 31 · Moderate
Price$0.30
Model IV—
P/IV—
Market implies +23.4%/yr vs model +8.0% · above model
IONQ
IonQ, Inc.
Valuation N/A
Technology Risk 37 · Moderate
Price$36.75
Model IV—
P/IV—
Market implies +55.1%/yr vs model +50.0% · above model
IONR
ioneer Ltd
Valuation N/A
Basic Materials Risk 37 · Moderate
Price$2.79
Model IV—
P/IV—
Limited data — see page
IONS
IONIS PHARMACEUTICALS INC
Valuation N/A
Healthcare Risk 45 · Elevated
Price$54.21
Model IV—
P/IV—
Market implies +9.6%/yr vs model +3.9% · above model
IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Valuation N/A
Healthcare Risk 34 · Moderate
Price$8.60
Model IV—
P/IV—
Market implies -50.0%/yr vs model +15.0% · below model
IPB
MERRILL LYNCH DEPOSITOR INC INDEXPLUS TRUST SERIES 2003-1
Valuation N/A
Financial Services
Price$24.94
Model IV—
P/IV—
Limited data — see page
IPCX
Inflection Point Acquisition Corp. III
Valuation N/A
Financial Services
Price$3.76
Model IV—
P/IV—
Limited data — see page
IPCXR
Inflection Point Acquisition Corp. III
Valuation N/A
Financial Services
Price$0.39
Model IV—
P/IV—
Limited data — see page
IPEX
Inflection Point Acquisition Corp. V
Valuation N/A
Financial Services
Price$8.10
Model IV—
P/IV—
Limited data — see page
IPEXR
Inflection Point Acquisition Corp. V
Valuation N/A
Financial Services
Price$0.55
Model IV—
P/IV—
Limited data — see page
IPFX
Inflection Point Acquisition Corp. VI
Valuation N/A
Financial Services
Price$10.05
Model IV—
P/IV—
Limited data — see page
IPHA
Innate Pharma SA
Valuation N/A
Healthcare Risk 54 · Elevated
Price$1.87
Model IV—
P/IV—
Limited data — see page
IPM
INTELLIGENT PROTECTION MANAGEMENT CORP.
Valuation N/A
Technology Risk 27 · Moderate
Price$1.88
Model IV—
P/IV—
Market implies +19.7%/yr vs model -1.1% · above model